checkAd

     662  0 Kommentare Hansen Medical(R) Announces Successful Enrollment of Initial Cohort in Artisan(R) U.S. Clinical Trial

    MOUNTAIN VIEW, CA--(Marketwired - Jul 6, 2015) -  Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it has completed enrollment in the initial evaluable cohort of the ARTISAN® clinical trial.

    The ARTISAN Atrial Fibrillation Trial is a prospective, single-arm, multi-center, US and OUS study designed to evaluate the safety and effectiveness of the Sensei® Robotic System and Artisan family of catheters for introducing and positioning specified commercially available RF ablation catheters in subjects with symptomatic, drug-refractory paroxysmal atrial fibrillation. The Bayesian designed study requires enrollment of an initial cohort of 125 patients, with subsequent enrollment permitted to support the end-point analysis. The trial has two primary endpoints: safety, defined as the absence of early onset of all major adverse events, and efficacy, defined as freedom from atrial fibrillation through one year.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Philips Electronics!
    Long
    23,21€
    Basispreis
    0,21
    Ask
    × 11,91
    Hebel
    Short
    26,96€
    Basispreis
    0,22
    Ask
    × 11,37
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    "We are excited to see the initial phase of enrollment completed in the IDE and are working closely with the investigators and FDA to expand the clinical indications for the Artisan catheter in the U.S. market. This patient cohort sets the initial timing to evaluate the trial endpoints and gain additional clinical indications in the U.S." said Cary Vance, President and Chief Executive Officer of Hansen Medical. "We believe our robotic technology brings enhanced control and predictability to these procedures, and addresses serious occupational hazards faced by physicians and their teams in the delivery of patient care."

    "This clinical trial is significant and sets a milestone for robotic technology in the treatment of patients with atrial fibrillation "said Dr. Joseph Gallinghouse, Texas Cardiac Arrhythmia Institute at St. David's Medical Center. "The team here at St. David's finds the Sensei Robotic System reduces radiation exposure to the operator, while the Artisan catheter predictably navigates and provides a stable platform during AF ablation, a procedure which can sometimes last for hours." Dr. Gallinghouse has significant experience with the Sensei Robotic System and Artisan catheter and has performed more than 1,200 procedures to date. 

    Seite 1 von 4




    Verfasst von Marketwired
    Hansen Medical(R) Announces Successful Enrollment of Initial Cohort in Artisan(R) U.S. Clinical Trial MOUNTAIN VIEW, CA--(Marketwired - Jul 6, 2015) -  Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it has completed enrollment in the initial evaluable cohort of the ARTISAN® clinical trial. …

    Schreibe Deinen Kommentar

    Disclaimer